Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by research analysts at Cowen in a research note issued on Wednesday, AnalystRatings.com reports.
A number of other research analysts have also recently commented on ESPR. Northland Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, August 29th. ValuEngine upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BidaskClub upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Stifel Nicolaus decreased their price target on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Finally, Goldman Sachs Group upgraded Esperion Therapeutics from a “sell” rating to a “neutral” rating and decreased their price target for the stock from $55.00 to $45.00 in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $70.44.
ESPR traded up $0.25 during trading hours on Wednesday, reaching $37.82. The company’s stock had a trading volume of 592,400 shares, compared to its average volume of 500,623. Esperion Therapeutics has a fifty-two week low of $33.13 and a fifty-two week high of $58.90. The stock has a market cap of $1.11 billion, a PE ratio of -5.02 and a beta of 1.86. The business’s 50-day moving average is $38.49 and its 200-day moving average is $42.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65.
In other news, major shareholder Target N. V. Biotech purchased 75,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were bought at an average cost of $37.30 per share, for a total transaction of $2,797,500.00. Following the completion of the purchase, the insider now directly owns 3,727,964 shares of the company’s stock, valued at $139,053,057.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Timothy M. Mayleben purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were purchased at an average price of $36.98 per share, for a total transaction of $184,900.00. Following the completion of the purchase, the chief executive officer now directly owns 83,663 shares of the company’s stock, valued at $3,093,857.74. The disclosure for this purchase can be found here. Insiders have acquired 167,500 shares of company stock worth $5,943,925 over the last 90 days. 7.70% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in ESPR. Aperio Group LLC acquired a new position in Esperion Therapeutics during the second quarter worth $29,000. Russell Investments Group Ltd. purchased a new stake in shares of Esperion Therapeutics during the second quarter worth $32,000. Tower Research Capital LLC TRC purchased a new stake in shares of Esperion Therapeutics during the third quarter worth $42,000. Bank of Montreal Can increased its position in shares of Esperion Therapeutics by 364.5% during the second quarter. Bank of Montreal Can now owns 2,671 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 2,096 shares during the period. Finally, Royal Bank of Canada increased its position in shares of Esperion Therapeutics by 38.1% during the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 811 shares during the period.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: Profit Margin
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.